

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87779

Anthony Robert Milnes COATES

Appln. No.: 10/534,054

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Unknown

Filed: May 06, 2005

For:

PAIN RELIEF AGENTS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/534,054

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,764

Gordon Kit

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373

CUSTOMER NUMBER

Date: March 22, 2006

2

Substitute for Form 1449	9 A & B/PTO		
INFOR STAT	RMATIO EMENT I	N DISCLOS BY APPLIC	SURE PE
(use	as many sh	eets as necesso	(V) MAR 2 2 2006
Sheet	1	of	Real Strain

olete if Known
10/534,054
Unknown
May 06, 2005
Anthony Robert Milnes
COATES
Unknown
Unknown
Q87779

			U.S. I	PATENT DOCUM	MENTS
Examiner Cite	Document Nu		Publication Date		
Initials*	No.1	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US 4,440,859		04-03-1984	Rutter, et al.
		US 4,530,901		07-23-1985	Weissmann
		US 4,582,800		04-15-1986	Crowl
		US 4,677,063		06-30-1987	Mark, et al.
		US 4,678,751		07-07-1987	Goeddel
		US 4,704,362		11-03-1987	Itakura, et al.
		US 4,710,463		12-01-1987	Murray
		US 4,757,006		07-12-1988	Toole, Jr., et al.
		US 4,766,075		08-23-1988	Goeddel, et al
		US 4,810,648		03-07-1989	Stalker
		US 5,856,305	Α	01-05-1999	Lucietto, et al.
		US. 6,117,421	A	09-12-2000	Morton, et al.

			F	OREIGN PA	TENT DOCUM	ENTS	
Examiner Cite Initials* No.1	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	
	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶	
		wo	02/40037	A2	05-23-2002	St. George's Enterprises Limited	
		wo	01/04344	A2	01-18-2001	Stressgen Biotechnologies Corporation	
		WO	96/16083	A1	05-30-1996	Italfarmaco S.P.A.	
		wo	99/35270	A1	07-15-1999	Stressgen Biotechnologies Corporation	
		WO	02/40517	A2	05-23-2002	St. George's Enterprises Limited	
		wo	02/40038	A2	05-23-2002	St. George's Enterprises Limited	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶		
		F. J. Andrews, et al., "Effect of iron chelation on inflammatory joint disease", Annals of the Rheumatic Diseases, 46, 327-333, (1987)			
	,	P. N. Baird, et al., "Cloning and Sequence Analysis of the 10 kDa Antigen Gene of Mycobacterium tuberculosis", Journal of General Microbiology 135, 931-939, (1989), XP-008005161			
		P. N. Baird, et al., "A major antigen from Mycobacterium tuberculosis which is homologous to the heat shock proteins groES from E.coli and the htpA gene product of Coxiella burneti", Nucleic Acids Research, Vol. 16, Number 18 page 9047, (1988), XP-001074008			
		M. Bassan, et al., "The identification of secreted heat shock 60 -like protein from rat glial cells and a human neuroblastoma cell line", Neuroscience Letters 250, 37-40, (1998)			

Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

	Complete if Known		
Substitute for Form 1449 A & B/PTO	Application Number	10/534,054	
INFORMATION DISCLOSURA P E	Confirmation Number	Unknown	
STATEMENT BY APPLICANT	Filing Date	May 06, 2005	
<u> </u>	First Named Inventor	Anthony Robert Milnes COATES	
(use as many sheets as necessary) MAR 2 2 2006	Art Unit	Unknown	
	Examiner Name	Unknown	
Sheet 2 of of	Attorney Docket Number	Q87779	

				U.S.	PATE	NT DOCU	MENTS	S		
		Doc	ument Numb	er						
Examiner Initials*	Cite No.1	Numb	er	Kind Code ² (if known)	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document			
		US								
		_		FOREI	GN PA	TENT DO	CUME	NTS		
Examiner Cite		Foreign Patent Document		Publication Da		Date	Name of Patentee or	75 1 1 6		
Initials*	No.1	Country Code ³	Number	• •	Code ⁵ nown)	MM-DD-Y	YYY	Applicant of Cited Document	Translation ⁶	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		J. T. Beech, et al., "CD4 ⁺ Th2 Cells Specific for Mycobacterial 65-kilodalton Heat Shock Protein Protect	
		Against Pristane-Induced Arthritis", The Journal of Immunology, 159, 3692-3697, (1997)	
		K. Bethke, et al., "Different Efficiency of Heat Shock Proteins (HSP) to Activate Human Monocytes and	
		Dendritic Cells: Superiority of HSP60", The Journal of Immunology, 169, 6141-6148, (2002)	
		V. L. D. Bonato, et al, "Identification and Characterization of Protective T Cells in hsp65 DNA-Vaccinated	
		and Mycobacterium tuberculosis-Infected Mice", Infection and Immunity, Vol. 66, No. 1, pp. 169-175, January 1998	
		A. C. Cavanagh, "Identification of early pregnancy factor as chaperonin 10: implications for understanding its role", Reviews of Reproduction, 1, 28-32, (1996)	
		H. Chiu, et al., "Differential Induction of Heme Oxygenase- 1 in Macrophages and Hepatocytes during Acetaminophen-Induced Hepatotoxicity in the Rat: Effects of Hemin and Biliverdin", Toxicology and Applied Pharmacology 181, 106-115, (2002)	
		A. R. M. Coates, et al., "Chaperonins in Health and Disease", Annals of NY Academy of Sciences, 851, 48-52, (1998)	
		A. R. M. Coates, et al., "The Unfolding Story of the Chaperonins", Biotechnology and Genetic Engineering Reviews", Vol. 16, pp. 393-405, April 1999	
		A. R. M. Coates, "Immunological Aspects of Chaperonins", The Chaperonins, Academic Press 267-296, (1996)	_
		I. R. Cohen, "Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination", Diabetologia, 45, 1468-1474, (2002)	
		N. Cranswick, et al., "Paracetamol Efficacy and Safety in Children: the First 40 Years", American Journal of Therapeutics, 7, 135-141, (2000)	
		H. L. F. Currey, et al., "Suppression of Adjuvant Disease in the Rat by Heterologous Antilymphocyte Globulin", J. Exp. Med., 127, 185-203, (1968)	
		D. Elias, "Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 1576-1580, February 1990	
		C. El-Khoury, et al., "Attenuation of Neuropathic Pain by Segmental and Supraspinal Activation of the Dorsal Column System in Awake Rats", Neuroscience Vol. 112, No. 3, pp. 541-553, (2002)	

		1	
Examiner Signature	<u>_1</u>	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

	Complete if Known		
Substitute for Form 1449 A & B/PTO	Application Number	10/534,054	
' INFORMATION DISCLOSURE S	Confirmation Number	Unknown	
INFORMATION DISCLOSURE PE STATEMENT BY APPLICANT 4	Filing Date	May 06, 2005	
		Anthony Robert Milnes	
· · · · · · · · · · · · · · · · · · ·	First Named Inventor	COATES	
(use as many sheets as necessary) MAR 2 2 2006	Art Unit	Unknown	
	Examiner Name	Unknown	
Sheet 3 of of	Attorney Docket Number	Q87779	

U.S. PATENT DOCUMENTS							
		Document Nu	mber				
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US					

FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials* No.1	Cite	Foreign Patent Document		Publication Date	Name of Patentee or			
	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶	

		NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.							
		S. B. Flohé, et al., "Human Heat Shock Protein 60 Induces Maturation of Dendritic Cells Versus a Th1-							
		Promoting Phenotype", The Journal of Immunology, 170, 2340-2348, (2003)							
		J. S. Friedland, et al., "Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells", Clin Exp Immunol, 91, 58-62, (1993)							
		A. Frisk, et al., "GroEL Heat Shock Protein of Haemophilus ducreyi: Association with Cell Surface and Capacity To Bind to Eukaryotic Cells", Infection and Immunity, Vol. 66, No. 3, pp. 1252-1257, March 1998							
		G. Furness, "A breath of fresh air", Scrip Magazine, Pharmaceutical issues in perspective, pp. 10-13, November 2004							
		S. E. Girardin, et al., "Intracellular vs extracellular recognition of pathogens - common concepts in mammals and flies", Trends in Microbiology, Vol. 10, No. 4, pp. 193-199, April 2002							
		A. P. Gobert, et al., "Helicobacter pylori Heat Shock Protein 60 Mediates Interleukin-6 Production by Macrophages via a Toll-like Receptor (TLR)-2-, TLR-4-, and Myeloid Differentiation Factor 88-independent Mechanism", The Journal of Biological Chemistry, Vol. 279, No. 1 pp. 245-250, Jan. 2, 2004							
		F. Goulhen, et al., "Subcellular Localization and Cytotoxic Activity of the GroEL-Like Protein Isolated from Actinobacillus actinomycetemcomitans", Infection and Immunity, Vol. 66, No. 11, pp. 5307-5313, Nov. 1998							
		C. Habich, et al., "Different heat shock protein 60 species share pro-inflammatory activity but not binding sites on macrophages", FEBS Letters, 533, 105-109, (2003)							
		B. Henderson, et al., "Molecular chaperones and disease", Inflammation Research, 45, (155-158), 1996							
		W. S. Hills, "Areas of Emerging Interest in Analgesia: Cardiovascular Complications", American Journal of Therapeutics, 9, 259-269, (2002)							
		S. Jindal, "Heat Shock Proteins in Infections and Immunity", Heat Shock Proteins conference handout, Cambridge Center Marriott, Cambridge, MA, September 29-30, 1994							
		S. A. Kanaan, et al., "Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain", Pain, 66, 373-379, (1996)							
		Kirby, et al., "Potent Bone-resorbing Mediator of Actinobacillus actinomycetemcomitans homologous to the Molecular Chaperone GroEL", J Clin Invest 96, 1185-1194, (1995)							

i		
Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

		Complete if Known		
Substitute for Form 1449 A & B/PTO		Application Number	10/534,054	
INFORMATION DISCLOSURE PE	_	Confirmation Number	Unknown	
		Filing Date	May 06, 2005	
STATEMENT BY APPLICANT	RO		Anthony Robert Milnes	
MAD 2 2	2008 🖸 /	First Named Inventor	COATES	
(use as many sheets as necessary MAR 22	(אָע שׁניטיז	Art Unit	Unknown	
	Ē	Examiner Name	Unknown	
Sheet 4 of Strapes	St.	Attorney Docket Number	Q87779	

U.S. PATENT DOCUMENTS								
		Document Number						
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	T			
	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶			

_		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.						
		A. Kol, et al., "Chlamydial Heat Shock Protein 60 Localizes in Human Atheroma and Regulates Macrophage Tumor Necrosis Factor-α and Matrix Metalloproteinase Expression", Circulation, 98, 300-307 (1998)						
		A. Kol, et al., "Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages", The Journal of Clinical Investigation, Vol. 103, No. 4, 571-577, February 1999						
		T. H. Kong, et al., "Mycobacterium tuberculosis expresses two chaperonin-60 homologs", Proc. Natl. Acad. Sci. USA, Vol. 90, 2608-2612, April 1993 Microbiology						
		R. A. Laskey, et al., "Nucleosomes are assembled by an acidic protein which binds histones and transfers them to DNA", Nature, Vol. 275, 416-420, October 5, 1978						
		J. Lewthwaite, et al., "Rhizobium leguminosarum chaperonin 60.3, but not chaperonin 60.1, induces cytokine production by human monocytes: activity is dependent on interaction with cell surface CD14", Cell Stress and Chaperonins, 7 (2) 130-136, (2002)						
		J. Lewthwaite, et al., "Circulating Human Heat Shock Protein 60 in the Plasma of British Civil Servants", Circulation, 106, 196-201, (2002)						
		J. Lewthwaite, et al., "Mycobacterium tuberculosis Chaperonin 60.1 Is a More Potent Cytokine Stimulator than Chaperonin 60.2 (Hsp 65) and Contains a CD14-Binding Domain", Infection and Immunity, Vol. 69, No. 12, 7349-7355, December 2001						
		D. B. Lowrie, et al., "Therapy of tuberculosis in mice by DNA vaccination", Nature, Vol. 400, 269-271, July 15, 1999						
		P. Matzinger, "An innate sense of danger", seminars in Immunology, Vol. 10, 399-415, (1998)						
		R. Medzhitov, et al., "Innate Immunity: The Virtues of a Nonclonal System of Recognition", Cell, Vol. 91, 295-298, October 31, 1997						
		S. Meghji, et al., "Mycobacterium tuberculosis Chaperonin 10 Stimulates Bone Resorption: A Potential Contributory Factor in Pott's Disease", J. Exp. Med., Vol. 186, No. 8, 1241-1246, October 20, 1997						
		W. E. Peetermans, et al., Infection and Immunity, Vol. 63, No. 9, 3454-3458, September 1995						
		J. H. L. Playfair, "Immunology at a Glance", Blackwell Scientific Publications, Ch. 27 & 30, (1979)						
		S. Ragno, et al., "A synthetic 10-kD heat shock protein (hsp10) from Mycobacterium tuberculosis modulates adjuvant arthritis", Clin Exp Immunol, 103, 384-390, (1996)						

· · · · · · · · · · · · · · · · · · ·	1		
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

			Сотр	lete if Known
Substitute for Form 1449	A & B/PTO		Application Number	10/534,054
INIEOD	MATION DIC	CLOSUDE	Confirmation Number	Unknown
OTATE	MATION DIS	CLUSURE	Filing Date	May 06, 2005
STATE	EMENT BY AF	PLICANI		Anthony Robert Milnes
, –	•	TLIVENT 40	First Named Inventor	COATES
(use d	as many sheets as r	MAR 2 2 2006	Art Unit	Unknown
		MAR 22	Examiner Name	Unknown
Sheet	5	6	Attorney Docket Number	Q87779
		THE TRADELLA		

	U.S. PATENT DOCUMENTS							
		Document Nur	nber					
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
		US	-					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite	Foreign Patent Document		Publication Date	Name of Patentee or	T		
	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation®	

		NON PATENT LITERATURE DOCUMENTS	· ·
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		J. C. Ranford, et al., "Chaperonins are cell-signalling proteins: the unfolding biology of molecular	
		chaperones", Expert Reviews in Molecular Medicine: http://www-ermm.cbcu.cam.ac.uk/0000201-5h.htm ,	
		September 15, 2000	
		N. A. Ranson, et al., "Review Article Chaperonins", Biochem. J., 333, 233-242, (1998), Great Britain	
		I Raz, et al., "β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein	
		peptide (DiaPep277): a randomized, double-blind, phase II trial", The Lancet, Vol. 358, 1749-1753, (2001)	
		K. Reddi, et al., "The Escherichia coli Chaperonin 60 (groEL) Is a Potent Stimulator of Osteoclast	
		Formation", Journal of Bone and Mineral Research, Vol. 13., No. 8, 1260-1266, (1998)	
		Y. Rha, et al., " Effect of Microbial Heat Shock Proteins on Airway Inflammation and	
		Hyperresponsiveness", The Journal of Immunology, 169, 5300-5307, (2002)	
		S. Sasu, et al., "Chlamydia pneumoniae and Chlamydial Heat Shock Protein 60 Stimulate Proliferation of	
		Human Vascular Smooth Muscle Cells via Toll-Like Receptor 4 and p44/p42 Mitogen-Activated Protein	ŀ
		Kinase Activation", Circulation Research, 89, 244-250, (2001)	ļ
		S. Steinfeld, et al., "Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-	
		inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with	
		rofecoxib", Rheumatology, 41 (suppl. 1), 23-27, (2002	ļ
		P. Tabona, et al., "Homogeneous Escherichia coli Chaperonin 60 Induces IL-1β and IL-6 Gene Expression	
		in Human Monocytes by a Mechanism Independent of Protein Conformation", The Journal of Immunology,	
		161, 1414-1421, (1998)	
		K. Takahashi, et al., "Analysis of heat shock proteins and cytokines expressed during early stages of	
		osteoarthritis in a mouse model", Osteoarthritis and Cartilage, 5, 321-329, (1997)	ļ
		S. J. Thompson, et al., "An Immunodominant Epitope from Mycobacterial 65-kDa Heat Shock Protein	
		Protects Against Pristane-Induced Arthritis", The Journal of Immunology, 160, 4628-4634, (1998)	
		J. D. Thompson, "Clustal W: improving the sensitivity of progressive multiple sequence alignment through	
		sequence weighting, position-specific gap penalties and weight matrix choice", Nucleic Acids Research,	
		Vol. 22, No. 22, 4673-4680, (1994)	<u> </u>

1		
Evaminas Cianatura	Date Considered	
Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

	HAR 2 B	E		
, when the same of		Complete if Known		
Substitute for Form 1449 A & B/PTO	TEAT & TRADE	Application Number	10/534,054	
INFORMATION DISCLOS	E	Confirmation Number	Unknown	
OTATEMENT DV A DVI IC	NT &	Filing Date	May 06, 2005	
STATEMENT BY APPLICA	TIVI 0000 D		Anthony Robert Milnes	
· Lung	2 2 1000 B	First Named Inventor	COATES	
(use as many sheets as necessary	" E	Art Unit	Unknown	
\ \frac{1}{\infty}	AT!	Examiner Name	Unknown	
Sheet 6 of	TRADENTA	Attorney Docket Number	Q87779	

U.S. PATENT DOCUMENTS					
		Document Number			
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document		Publication Date	Name of Patentee or	T	
Initials*	- 11	Country Code ³	Number⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		W. van Eden, et al., "Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis", Nature Vol. 331, 171-173, January 14, 1988	
		E. M. E. Verdegaal, et al., "Heat Shock Protein 65 Induces CD62e, CD106, and CD54 on Cultured Human Endothelial Cells and Increases Their Adhesiveness for Monocytes and Granulocytes", The Journal of Immunology, 157, 369-376, (1996)	
		V. R. Windrow, et al., "Arthritogenic potential of the 65 kDa stress protein - an experimental model", Annals of the Rheumatic Diseases, 53, 197-201, (1994)	
		N. Yoshida, et al., "Chaperonin turned insect toxin", Nature, 411, p. 44, (2001)	
		U. Zügel, et al., "Role of Heat Shock Proteins in Protection from and Pathogenesis of Infectious Diseases", Clinical Microbiology Reviews, Vol. 12, No. 1, p. 19-39, January 1999	
		XP-002203460, EBI accession number Q59573; 60 kDa chaperonin	
			<u> </u>

Evaminar Signatura	Date Considered	
Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.